AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02915861 — intervention group
Intervention type: OTHER
Intervention: Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood
Description: EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
Study NCT02915861 — intervention group
Intervention type: OTHER
Intervention: Blood+Skin sample
Description: Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
Study NCT02552355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
Study NCT02552355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
Study NCT02552355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of matching placebo during a 12 week exercise training program.
Study NCT02552355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Daily administration of matching placebo during a 12 week exercise training program.
Study NCT02552355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Beverage
Description: Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
Study NCT03818659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided M.A.P. BP Improvement Program
Description: Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
Study NCT03818659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Support M.A.P. BP Improvement Program
Description: Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control.
Study NCT02552355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Beverage
Description: Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
Study NCT01147549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C14]AZD9668
Description: Oral Solution 60 mg Single Dose
Study NCT04311619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J radiotracer
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
Study NCT02552355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Beverage
Description: Supervised aerobic exercise 3 days per week followed by a protein drink
Study NCT02935231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: 1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
Study NCT04473261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Complex
Description: Iodine Complex capsule (200mg) will be given three times a day
Study NCT04473261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Complex
Description: Iodine Complex syrup form (40ml) will be given three times a day
Study NCT04473261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty capsule will be given as placebo
Study NCT02935231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minimal Cessation Advice (MCA)
Description: Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
Study NCT02935231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health warning leaflet
Description: An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
Study NCT02935231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
Study NCT03716323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: immediate premolar implant with xenograft and allograft
Description: * A peritome will be used for atraumatic extraction of remaining roots.~* The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~* Copious normal saline irrigation and curettage will be performed.~* In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~* In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)
Study NCT02887924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff; Fisher and Paykel, Auckland, New Zealand
Description: Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
Study NCT02887924 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neopuff; Fisher and Paykel, Auckland, New Zealand
Description: Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
Study NCT01578317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine plus AS03 adjuvant
Description: H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
Study NCT01578317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 vaccine without adjuvant
Description: H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
Study NCT04487964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Licorice extract
Description: LICORICE CAPSULES; 250 mg standardized extract (25% Glycyrrhizin - 62.5 mg) For 10 days, with measuring blood pressure daily.~Dose:~One capsule, twice daily, before meals. Boswellia serrata Gum Resin; B. serrate contains volatile oils (5-15%), pure resin (55-66%), and mucus (12-23%). The resin contains terpenoids, phenolic compounds, flavonoids, and phenylpropanoids. More than 12 different Boswellic acids have been identified, the amounts of 11-keto-β-boswellic acid KBA is 3-4.7% and acetyl-11-keto-β-boswellic acid(AKBA) is 2.2-2.9%, Dose: 2 gm, 4 times daily For 15 days, Boswellia Gum Resin is administered by chewing for a half-hour
Study NCT04515420 — intervention group
Intervention type: DRUG
Intervention: noradrenaline
Description: noradrenaline infusion
Study NCT01609582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 tablets
Study NCT01609582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets
Study NCT03129776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 13C-Pyruvate
Description: The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
Study NCT03129776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: 18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
Study NCT04445233 — intervention group
Intervention type: DEVICE
Intervention: COVID-19 IgM-IgG Rapid Test
Description: Used to detect the IgG and IgM antibodies of the novel coronavirus in human whole blood (capillary or venous), serum, or plasma.
Study NCT03091868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Matching placebo capsules. Oral administration.
Study NCT03091868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25
Description: Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
Study NCT03091868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
Study NCT04311619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MR
Description: Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
Study NCT01356940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine ER
Description: dalfampridine ER 10mg bid for 4 weeks
Study NCT01356940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalfampridine ER
Description: dalfampridine ER 10mg bid for 4 weeks
Study NCT02487719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
Study NCT03091868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 25 mg
Description: BIA 6-512 capsules strengths 25 mg. Oral administration.
Study NCT03091868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512 100 mg
Description: BIA 6-512 capsules strengths 100 mg. Oral administration.
Study NCT03091933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLIDE
Description: Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
Study NCT05449522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: High dose of vitamin D with 576,000 IU on the 3rd post-trauma day and 432,000 IU on the 10th post-trauma day (1,008,000 IU in total) is given orally or enterally via a feeding tube
Study NCT05449522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium-chain triglyceride (MCT)
Study NCT02030938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SERI® Surgical Scaffold
Description: Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
Study NCT01138839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
Study NCT01138839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile water
Description: Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
Study NCT03398200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
Study NCT03398200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Hyperbaric Oxygen Therapy
Description: The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
Study NCT02127593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
Study NCT02127593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
Description: Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
Study NCT01667692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.\[1\] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
Study NCT01667692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithmycin
Description: Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
Study NCT03311529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Relaxation
Description: 10 training sessions (90 min. each) in Applied Relaxation (group format)
Study NCT00121095 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Samarium Sm-153 lexidronam + Docetaxel
Description: 1 mCi/kg Sm153 + 75 mg/m2 docetaxel
Study NCT03901885 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Female Sexual Function Index questionnaire
Description: Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
Study NCT02349542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (\~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
Study NCT00560768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ovatio VR 6250 or DR6550
Description: The study requires the implantation of locally approved material:~* A right ventricular defibrillation lead~* In case of use of a dual chamber ICD a right atrial pacing lead~* A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar.
Study NCT00498524 — intervention group
Intervention type: DEVICE
Intervention: ICD
Description: Received an ICD
Study NCT00498524 — intervention group
Intervention type: DEVICE
Intervention: ICD
Description: Have not received an ICD
Study NCT00992277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation and skin resurfacing
Study NCT01132274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
Study NCT01132274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
Study NCT00543543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: GARDASIL
Description: GARDASIL (quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
Study NCT00543543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
Study NCT00543543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: V503
Description: V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
Study NCT03325270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous fumarate
Description: labeled iron as Ferrous Fumarate
Study NCT03325270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous fumarate + prebiotics
Description: labeled iron as Ferrous Fumarate + galacto-oligosaccharides
Study NCT03325270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: labeled ferrous sulfate + prebiotics
Description: labeled iron as Ferrous Sulfate + galacto-oligosaccharides
Study NCT03813043 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam injection
Description: Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
Study NCT01046162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Single tablet
Study NCT00033605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Study NCT00033605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT00033605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Study NCT00033605 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Study NCT02530463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study NCT02530463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02530463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00309478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600mg/m2
Study NCT00309478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 40mg/m2
Study NCT00309478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil implant
Description: Fluorouracil 600mg/m2
Study NCT00309478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Zoladex 3.6mg/28 days for 3 years
Study NCT00309478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Nolvadex 20mg/day for 5 years
Study NCT01033188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single bundle
Description: Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon.